Report Overview
Nuclear medicine, a type of imaging that uses radioactive materials, is a useful tool to detect and also treat prostate cancer. It is a form of diagnostic imaging that helps radiologists determine the stage of cancer.
The global Prostate Cancer Nuclear Medicine Diagnostics market size was estimated at USD 720 million in 2023 and is projected to reach USD 1782.91 million by 2032, exhibiting a CAGR of 10.60% during the forecast period.
North America Prostate Cancer Nuclear Medicine Diagnostics market size was estimated at USD 223.25 million in 2023, at a CAGR of 9.09% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Prostate Cancer Nuclear Medicine Diagnostics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Prostate Cancer Nuclear Medicine Diagnostics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Prostate Cancer Nuclear Medicine Diagnostics market in any manner.
Global Prostate Cancer Nuclear Medicine Diagnostics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical
Market Segmentation (by Type)
SPECT
PET
Market Segmentation (by Application)
Hospitals
Clinics
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Prostate Cancer Nuclear Medicine Diagnostics Market
Overview of the regional outlook of the Prostate Cancer Nuclear Medicine Diagnostics Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Prostate Cancer Nuclear Medicine Diagnostics
1.2 Key Market Segments
1.2.1 Prostate Cancer Nuclear Medicine Diagnostics Segment by Type
1.2.2 Prostate Cancer Nuclear Medicine Diagnostics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Prostate Cancer Nuclear Medicine Diagnostics Market Overview
2.1 Global Market Overview
2.1.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape
3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Manufacturers (2019-2025)
3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Manufacturers (2019-2025)
3.3 Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Prostate Cancer Nuclear Medicine Diagnostics Sales Sites, Area Served, Product Type
3.6 Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Situation and Trends
3.6.1 Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Prostate Cancer Nuclear Medicine Diagnostics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Prostate Cancer Nuclear Medicine Diagnostics Industry Chain Analysis
4.1 Prostate Cancer Nuclear Medicine Diagnostics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Prostate Cancer Nuclear Medicine Diagnostics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2019-2025)
6.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Market Share by Type (2019-2025)
6.4 Global Prostate Cancer Nuclear Medicine Diagnostics Price by Type (2019-2025)
7 Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Sales by Application (2019-2025)
7.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) by Application (2019-2025)
7.4 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Growth Rate by Application (2019-2025)
8 Prostate Cancer Nuclear Medicine Diagnostics Market Consumption by Region
8.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.1.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Region
8.2 North America
8.2.1 North America Prostate Cancer Nuclear Medicine Diagnostics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Prostate Cancer Nuclear Medicine Diagnostics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Prostate Cancer Nuclear Medicine Diagnostics Market Production by Region
9.1 Global Production of Prostate Cancer Nuclear Medicine Diagnostics by Region (2019-2025)
9.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2019-2025)
9.3 Global Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Prostate Cancer Nuclear Medicine Diagnostics Production
9.4.1 North America Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.4.2 North America Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Prostate Cancer Nuclear Medicine Diagnostics Production
9.5.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.5.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Prostate Cancer Nuclear Medicine Diagnostics Production (2019-2025)
9.6.1 Japan Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.6.2 Japan Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Prostate Cancer Nuclear Medicine Diagnostics Production (2019-2025)
9.7.1 China Prostate Cancer Nuclear Medicine Diagnostics Production Growth Rate (2019-2025)
9.7.2 China Prostate Cancer Nuclear Medicine Diagnostics Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Blue Earth Diagnostics
10.1.1 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.1.2 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.1.4 Blue Earth Diagnostics Business Overview
10.1.5 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
10.1.6 Blue Earth Diagnostics Recent Developments
10.2 PETNET Solutions
10.2.1 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.2.2 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.2.4 PETNET Solutions Business Overview
10.2.5 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
10.2.6 PETNET Solutions Recent Developments
10.3 Cardinal Health
10.3.1 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.3.2 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
10.3.5 Cardinal Health Business Overview
10.3.6 Cardinal Health Recent Developments
10.4 Lantheus Medical Imaging
10.4.1 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.4.2 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.4.4 Lantheus Medical Imaging Business Overview
10.4.5 Lantheus Medical Imaging Recent Developments
10.5 Jubilant Pharma
10.5.1 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.5.2 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.5.4 Jubilant Pharma Business Overview
10.5.5 Jubilant Pharma Recent Developments
10.6 NCM-USA
10.6.1 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.6.2 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.6.4 NCM-USA Business Overview
10.6.5 NCM-USA Recent Developments
10.7 Progenics Pharma
10.7.1 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.7.2 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.7.4 Progenics Pharma Business Overview
10.7.5 Progenics Pharma Recent Developments
10.8 Telix Pharma
10.8.1 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.8.2 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.8.4 Telix Pharma Business Overview
10.8.5 Telix Pharma Recent Developments
10.9 ImaginAb
10.9.1 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.9.2 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.9.4 ImaginAb Business Overview
10.9.5 ImaginAb Recent Developments
10.10 Theragnostics
10.10.1 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.10.2 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.10.4 Theragnostics Business Overview
10.10.5 Theragnostics Recent Developments
10.11 Novartis
10.11.1 Novartis Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.11.2 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.11.4 Novartis Business Overview
10.11.5 Novartis Recent Developments
10.12 Alliance Medical
10.12.1 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Basic Information
10.12.2 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product Overview
10.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product Market Performance
10.12.4 Alliance Medical Business Overview
10.12.5 Alliance Medical Recent Developments
11 Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Region
11.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast
11.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country
11.2.3 Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Region
11.2.4 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Prostate Cancer Nuclear Medicine Diagnostics by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Prostate Cancer Nuclear Medicine Diagnostics by Type (2025-2032)
12.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Prostate Cancer Nuclear Medicine Diagnostics by Type (2025-2032)
12.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Application (2025-2032)
12.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) Forecast by Application
12.2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Prostate Cancer Nuclear Medicine Diagnostics Market Size Comparison by Region (M USD)
Table 5. Global Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Nuclear Medicine Diagnostics as of 2022)
Table 10. Global Market Prostate Cancer Nuclear Medicine Diagnostics Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Prostate Cancer Nuclear Medicine Diagnostics Sales Sites and Area Served
Table 12. Manufacturers Prostate Cancer Nuclear Medicine Diagnostics Product Type
Table 13. Global Prostate Cancer Nuclear Medicine Diagnostics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Prostate Cancer Nuclear Medicine Diagnostics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
Table 22. Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Type (K MT)
Table 23. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (M USD)
Table 24. Global Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) by Type (2019-2025)
Table 25. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2019-2025)
Table 26. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) by Type (2019-2025)
Table 27. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Share by Type (2019-2025)
Table 28. Global Prostate Cancer Nuclear Medicine Diagnostics Price (USD/MT) by Type (2019-2025)
Table 29. Global Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) by Application
Table 30. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
Table 31. Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Application (2019-2025) & (K MT)
Table 32. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2019-2025)
Table 33. Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Application (2019-2025) & (M USD)
Table 34. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2019-2025)
Table 35. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Growth Rate by Application (2019-2025)
Table 36. Global Prostate Cancer Nuclear Medicine Diagnostics Sales by Region (2019-2025) & (K MT)
Table 37. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Region (2019-2025)
Table 38. North America Prostate Cancer Nuclear Medicine Diagnostics Sales by Country (2019-2025) & (K MT)
Table 39. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales by Region (2019-2025) & (K MT)
Table 41. South America Prostate Cancer Nuclear Medicine Diagnostics Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales by Region (2019-2025) & (K MT)
Table 43. Global Prostate Cancer Nuclear Medicine Diagnostics Production (K MT) by Region (2019-2025)
Table 44. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2019-2025)
Table 46. Global Prostate Cancer Nuclear Medicine Diagnostics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Prostate Cancer Nuclear Medicine Diagnostics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Prostate Cancer Nuclear Medicine Diagnostics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Prostate Cancer Nuclear Medicine Diagnostics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Prostate Cancer Nuclear Medicine Diagnostics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 52. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 53. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Blue Earth Diagnostics Business Overview
Table 55. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
Table 56. Blue Earth Diagnostics Recent Developments
Table 57. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 58. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 59. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. PETNET Solutions Business Overview
Table 61. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
Table 62. PETNET Solutions Recent Developments
Table 63. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 64. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 65. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics SWOT Analysis
Table 67. Cardinal Health Business Overview
Table 68. Cardinal Health Recent Developments
Table 69. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 70. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 71. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Lantheus Medical Imaging Business Overview
Table 73. Lantheus Medical Imaging Recent Developments
Table 74. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 75. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 76. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Jubilant Pharma Business Overview
Table 78. Jubilant Pharma Recent Developments
Table 79. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 80. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 81. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. NCM-USA Business Overview
Table 83. NCM-USA Recent Developments
Table 84. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 85. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 86. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Progenics Pharma Business Overview
Table 88. Progenics Pharma Recent Developments
Table 89. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 90. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 91. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. Telix Pharma Business Overview
Table 93. Telix Pharma Recent Developments
Table 94. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 95. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 96. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. ImaginAb Business Overview
Table 98. ImaginAb Recent Developments
Table 99. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 100. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 101. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Theragnostics Business Overview
Table 103. Theragnostics Recent Developments
Table 104. Novartis Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 105. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 106. Novartis Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 107. Novartis Business Overview
Table 108. Novartis Recent Developments
Table 109. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Basic Information
Table 110. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product Overview
Table 111. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 112. Alliance Medical Business Overview
Table 113. Alliance Medical Recent Developments
Table 114. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Region (2025-2032) & (K MT)
Table 115. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Region (2025-2032) & (M USD)
Table 116. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Country (2025-2032) & (K MT)
Table 117. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 118. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Country (2025-2032) & (K MT)
Table 119. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 120. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Region (2025-2032) & (K MT)
Table 121. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Region (2025-2032) & (M USD)
Table 122. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Country (2025-2032) & (K MT)
Table 123. South America Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 124. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast by Country (2025-2032) & (Units)
Table 125. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Country (2025-2032) & (M USD)
Table 126. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Type (2025-2032) & (K MT)
Table 127. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Type (2025-2032) & (M USD)
Table 128. Global Prostate Cancer Nuclear Medicine Diagnostics Price Forecast by Type (2025-2032) & (USD/MT)
Table 129. Global Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) Forecast by Application (2025-2032)
Table 130. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Prostate Cancer Nuclear Medicine Diagnostics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD), 2019-2032
Figure 5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (M USD) (2019-2032)
Figure 6. Global Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (M USD)
Figure 11. Prostate Cancer Nuclear Medicine Diagnostics Sales Share by Manufacturers in 2023
Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Manufacturers in 2023
Figure 13. Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Prostate Cancer Nuclear Medicine Diagnostics Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type
Figure 18. Sales Market Share of Prostate Cancer Nuclear Medicine Diagnostics by Type (2019-2025)
Figure 19. Sales Market Share of Prostate Cancer Nuclear Medicine Diagnostics by Type in 2023
Figure 20. Market Size Share of Prostate Cancer Nuclear Medicine Diagnostics by Type (2019-2025)
Figure 21. Market Size Market Share of Prostate Cancer Nuclear Medicine Diagnostics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application
Figure 24. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2019-2025)
Figure 25. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application in 2023
Figure 26. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2019-2025)
Figure 27. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application in 2023
Figure 28. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Growth Rate by Application (2019-2025)
Figure 29. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Region (2019-2025)
Figure 30. North America Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Country in 2023
Figure 32. U.S. Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Prostate Cancer Nuclear Medicine Diagnostics Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Prostate Cancer Nuclear Medicine Diagnostics Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Country in 2023
Figure 37. Germany Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Region in 2023
Figure 44. China Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (K MT)
Figure 50. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Country in 2023
Figure 51. Brazil Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Prostate Cancer Nuclear Medicine Diagnostics Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Prostate Cancer Nuclear Medicine Diagnostics Production Market Share by Region (2019-2025)
Figure 62. North America Prostate Cancer Nuclear Medicine Diagnostics Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Prostate Cancer Nuclear Medicine Diagnostics Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Prostate Cancer Nuclear Medicine Diagnostics Production (K MT) Growth Rate (2019-2025)
Figure 65. China Prostate Cancer Nuclear Medicine Diagnostics Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Type (2025-2032)
Figure 70. Global Prostate Cancer Nuclear Medicine Diagnostics Sales Forecast by Application (2025-2032)
Figure 71. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Application (2025-2032)
